Skip to main content
. 2021 Feb 8;39(12):1329–1338. doi: 10.1200/JCO.20.01375

FIG 3.

FIG 3.

Kaplan-Meier estimate of (A) PFS in patients with ABC, n = 94; (B) OS for patients with ABC; and (C) PFS in patients with GCB. ABC, activated B-cell–like; GCB, germinal center B-cell–like; OS, overall survival; PFS, progression-free survival; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2CHOP, lenalidomide plus R-CHOP.